; or (bb) described in subsection (b)(1)(B), but only if such requestor initiates such request in conjunction with a request for the Secretary to determine whether such drug is generally recognized as safe and effective within the meaning of section 201(p)(1), which is filed by the Secretary under subparagraph (A)(ii)(I). The Secretary is not required to complete review of the request for a change described in subclause (II) if the Secretary determines, in accordance with subparagraph (D), that there is an inadequate basis to find the drug is generally recognized as safe and effective under paragraph (1) and issues a final order announcing that determination. (ii) Withdrawal of request The requestor may withdraw a request under this paragraph, according to the procedures established by the Secretary. Notwithstanding any other provision of this section, if such request is withdrawn, the Secretary shall cease proceedings under this subparagraph. (C) Product differentiation (i) In general A final administrative order issued in response to a request under this paragraph shall have the effect of providing the order requestor (or the licensees, assignees, or successors in interest of such requestor with respect to the subject of such order and listed under clause (v)) the exclusive right, for a period of 2 years, to market drugs under this section incorporating changes described in clause (ii), subject to the limitations under clause (iv), and beginning on the date the requestor (or any such licensees, assignees, or successors in interest of such requestor) may lawfully market such drugs pursuant to the order. (ii) Changes described A change described in this clause is a change subject to an order specified in clause (i), which— (I) permits a drug to contain an active ingredient not previously incorporated in a marketed drug listed in clause (iii)